Role of genetic variability in the renin-angiotensin system in diabetic and nondiabetic renal disease

Seminars in Nephrology

Volumn 21, Issue 6, 2001, Pages 580-592

  Boonstra, Arnold ^a   De Zeeuw, Dick ^a   De Jong, Paul E ^a   Navis, Gerjan ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; GENETIC VARIABILITY; HUMAN; KIDNEY FUNCTION; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; RENAL DIABETES; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

EID: 0035181981     PISSN: 02709295     EISSN: None     Source Type: Journal    
DOI: 10.1053/snep.2001.26804     Document Type: Article

References (105)

1. Progression of renal insufficiency: A simple method of estimation
2. Role of patient factors in resistance to antiproteinuric intervention
3. An insertion deletion polymorphism in the angiotensin converting enzyme gene accounts for half of the variance of serum enzyme levels
4. Freely associating
5. Association between the angiotensin converting enzyme (I/D) polymorphism and diabetic nephropathy: A methodological appraisal and systematic review
6. Hypertension: Genes and environment
7. Hypertension as a complex trait amenable to genetic analysis: Basic strategies and integrative approaches
8. Endothelium derived relaxing factor/nitric oxide modulates angiotensin II action in the isolated microperfused rabbit afferent but not efferent arteriole
9. Angiotensin II receptor type 1 gene expression in human glomerulonephritis and diabetes mellitus
10. Angiotensin converting enzyme is upregulated in the proximal tubule of rats with intense proteinuria
11. Will genetics revolutionize medicine? Sounding board
12. Regional angiotensin II production in essential hypertension and renal artery stenosis
13. Ethnic differences in angiotensin gene polymorphism
14. Angiotensin converting enzyme polymorphism: Potential silencer motif and impact on progression of IgA nephropathy
15. Angiotensin converting enzyme in the human heart. Effect of insertion deletion polymorphism
16. Renal ACE immunohistochemical localization in NIDDM patients with nephropathy
17. Genotypic influence on plasma dipeptidyl carboxy peptidase- 1 activity in hypertensives
18. Renin-angiotensin system gene polymorphisms: Potential mechanisms for their association with cardiovascular diseases
19. Genotype-phenotype relationships for the renin-angiotensin system in the normal population
20. Angiotensin converting enzyme gene polymorphism has no influence on the circulating renin-angiotensin aldosterone system or blood pressure in normal subjects
21. The deletion polymorphism of the angiotensin converting enzyme is related to phenotypic differences in human arteries
22. The angiotensin converting enzyme gene polymorphism and responses to angiotensins and bradykinin in the human forearm
23. Angiotensin I to II conversion in the human forearm and leg. Effect of the ACE (I/D) polymorphism
24. Enhanced pressor response to angiotensin I in normotensive men with the deletion genotype (DD) for angiotensin converting enzyme
25. High sodium intake reveals phenotype differences in ACE (I/D) polymorphism
26. Physiology and pathophysiology of the adipose renin-angiotensin system
27. Angiotensingen's role in angiotensin formation, renin release and renal hemodynamics in isolated perfused rat kidney
28. Evidence for tissue specific activation of renal angiotensinogen mRNA expression in chronic stable experimental heart failure
29. Kinetics of the human renin and human substrate action
30. Determinants of interindividual renin and prorenin variation. Evidence for a sexual dimorphism of (pro-) renin in humans
31. Prorenin, renin, angiotensinogen and ACE in normal and failing human hearts: Evidence for renin-binding
32. Biochemistry and regulation of angiotensinogen
33. Assignment by in situ hybridisation of the angiotensinogen gene to chromosome band 1q 4, the same region as the human renin gene
34. Molecular basis of human hypertension: Role of angiotensinogen
35. Detection and characterization of new mutations in the human angiotensinogen gene
36. A nucleotide substitution in the promoter region of human angiotensinogen is associated with essential hypertension and affects basal transcription in vitro
37. Angiotensinogen T 235 expression is elevated in decidual spiral arteries
38. A mutation of the angiotensinogen in a patient with preecclampsia leads to altered kinetics of the renin-angiotensin system
39. Blunted renal vascular response to angiotensin II is associated with a common variant of the angiotensinogen gene and obesity
40. Angiotensin II type I receptor gene polymorphisms in human essential hypertension
41. Angiotensin II type I receptor polymorphism predicts response to losartan and angiotensin II
42. Angiotensin II sensitivity is associated with the angiotensin II type I receptor A 1166C polymorphism in essential hypertensives on a high sodium diet
43. Angiotensin II type 1 receptor A1166C gene polymorphism is associated with increased response to angiotensin II in human arteries
44. Angiotensin II type I receptor polymorphism is associated with an increased vascular reactivity in the human mammary artery in vitro
45. The angiotensin II type 1 receptor gene polymorphism is associated with coronary artery vasoconstriction
46. 1166 A/C polymorphism of the angiotensin II type I receptor gene and the response to short term infusion of angiotensin II
47. Abnormal renal function, sodium-volume homeostasis and renin system behaviour in normal renin essential hypertension: The evolution of the nonmodulator concept
48. Does the renin-angiotensin system determine the renal and systemic hemodynamic response to sodium?
49. Effects of gender and phenotype on the phenotypic expression of nonmodulating hypertension
50. Angiotensin-converting enzyme gene (I/D) polymorphism and renal disease
51. The progression of renal disease
52. Pharmacogenomics: A new approach to individual therapy of hypertension?
53. Polymorphism in angiotensin converting enzyme gene and progression of IgA nephropathy
54. Polymorphism of the angiotensin converting enzyme gene and clinical aspects of IgA nephropathy
55. Genetic variation in the renin-angiotensin system and membranous glomemlonephritis
56. Angiotensin converting enzyme gene polymorphism in patients with minimal change nephrotic syndrome and focal segemental glomemlosclerosis
57. Angiotensin converting enzyme gene I/D polymorphism in essential hypertension and nephroangiosclerosis
58. The deletion polymorphism of the angiotensin converting enzyme gene is associated with target organ damage in essential hypertension
59. Genetic risk for renal artery stenosis: Association with deletion polymorphism in angiotensin converting enzyme gene
60. The deletion/insertion polymorphism of the angiotensin converting enzyme gene and cardiovascular-renal risk
61. Insertion/deletion angiotensin converting enzyme gene polymorphism affects the microvascular structure of the kidney in non-diabetic renal disease
62. Endothelial cell damage and angiotensin converting enzyme insertion/deletion genotype in elderly hypertensive patients
63. DD Angiotensin converting enzyme gene polymorphism is associated with endothelial dysfunction in normal humans
64. Angiotensin converting enzyme gene polymorphism is associated with endothelium dependent vasodilation in never treated hypertensive patients
65. Exclusion of the ACE (D/I) gene polymorphism as a determinant of endothelial dysfunction
66. Familial clustering of diabetic kidney disease: Evidence for genetic susceptibility to diabetic nephropathy
67. Familial factors determine the development of diabetic nephropathy in patients with IDDM
68. Familial predisposition to renal disease in two generations of Pima Indians with type II (non-insulin-dependent) diabetes mellitus
69. Raised arterial pressure in parents of proteinuric insulin-dependent diabetics
70. Renal changes on hyperglycemia and angiotensin converting enzyme in type I diabetes
71. Angiotensin convening enzyme gene polymorphism and renal hemodynamic function in early diabetes
72. Relationship between glomerular hyperfiltration and ACE insertion/deletion polymorphism in type I diabetic children and adolescents
73. Lack of synergism between poor long-term glycaemic control and three gene polymorphisms of the renin angiotensin system on risk of developing diabetic nephropathy in type I diabetic patients
74. Metaanalysis of association of insertion/deletion polymorphism of angiotensin I converting enzyme gene with diabetic nephropathy and retinopathy
75. Evaluation of risk factors for the development of nephropathy in patients with IDDM: Insertion/deletion polymorphism, hypertension and metabolic control
76. Diabetic nephropathy and the insertion/deletion polymorphism of the angiotensin converting enzyme gene. Meta-analysis
77. Prognostic value of angiotensin-I-converting enzyme I/D polymorphism for nephropathy in type I diabetes mellitus
78. Contribution of genetic polymorphisms in the renin-angiotensin system to the development of renal complications in insulin-dependent diabetes mellitus
79. Familial risk, age at onset, and cause of end-stage renal disease in white Americans
80. Effect of deletion polymorphism of angiotensin converting enzyme gene on progression of diabetic nepropathy during inhibition of angiotensin converting enzyme: Observational follow-up
81. Angiotensin I converting enzyme gene polymorphism in non-insulin dependent diabetes mellitus
82. Association of the angiotensin I converting enzyme gene deletion polymorphism with early onset of end stage renal failure in PKD 1 adult polycystic kidney disease
83. Association between angiotensin converting enzyme gene polymorphism and failure of renoprotective therapy
84. Risk factors for long term renal function loss after renal transplantation: A role for the angiotensin converting enzyme (insertion/deletion) polymorphism
85. Angiotensin converting enzyme genotype and renal allograft survival
86. ACE genotype and ACE inhibitors induced renoprotection in chronic proteinuric nephropathies
87. Association of angiotensinogen gene T 235 variant with progression of immunoglobulin A nephropathy in caucasian patients
88. ACE (I/D) genotype as a predictor of the magnitude and duration of the response to an ACE-inhibitor drag (enalaprilat) in humans
89. Renal hemodynamic changes induced by captopril and angiotensin converting enzyme gene polymorphism
90. ACE gene polymorphism does not determine short-term renal response to ACE-inhibition in proteinuric patients
91. Role of the deletion polymorphism of the angiotensin converting enzyme gene in the progression and therapeutic responsiveness of IgA nephropathy
92. Gene polymorphisms of angiotensin converting enzyme and endothelial nitric oxide synthase in patients with primary glomerulonephritis
93. Association of angiotensin converting enzyme gene polymorphism with susceptibility to antiproteinuric effect of angiotensin I converting enzyme inhibitors
94. Angiotensin converting enzyme polymorphism: Potential significance in nephrology
95. Angiotensin convening enzyme (ACE) gene polymorphisms determines the antiproteinuric and systemic hemodynamic effects of enalapril in patients with proteinuric renal disease
96. Angiotensin converting enzyme gene polymorphism and antiproteinuric response to renoprotective therapy
97. ACE (I/D) polymorphism and short-term response ro ACE-inhibition: Role of sodium status
98. Chronic proteinuric nephropathies II. Outcomes and response to treatment in a prospective cohort of 352 patients: Differences between women and men in relation to the ACE gene polymorphism
99. Effect of angiotensin converting enzyme (ACE) gene polymorphisms on progression of renal disease and the influence of ACE inhibition in IDDM patients
100. Angiotensin converting enzyme (ACE) gene polymorphism and ACE inhibition in diabetic nephropathy
101. Benefit of renoprotective therapy in chronic renal failure: Impact of pre-study renal function decline and ACE (I/D) polymorphism
102. Deletiontype allele of the angiotensin-converting enzyme gene is associated with progressive ventricular dilatation after anterior myocardial infarction. Captopril and Thrombolysis Study investigators
103. Activated tissue renin-angiotensin systems add to the progression of heart failure